REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's Inflation Reduction Act (IRA), but will look at refining the programme.

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior ...

In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi ...

In Part 6 of the Life Sciences Industry Report, we’ve collated key thought leadership from 2024 that looks at ways in which ...